A business that is poised to transform the UK’s self-care market has secured a GBP3.2 million investment in a funding round led by Praetura Ventures
Maxwellia, which is based at Alderley Park in Cheshire, aims to give people easier and faster access to the treatments they need by converting prescription-only medicines to versions that can be bought in a pharmacy.
Founded in 2013 by chief executive Anna Maxwell – a pharmacist with over 20 years’ experience, Maxwellia specialises in ‘switching’, a process in which prescription only medication is reclassified and made available over the counter. It already has three applications under assessment with the MHRA, and is currently awaiting approval of its first game-changing women’s health product following a public consultation.
‘Switching’ widens the access to medicine, supports self-care and patient wellbeing while reducing the burden on public services such as GPs. It is a rigorous process regulated by the MHRA, and previous well-known examples of switches include Nurofen, Canesten and Viagra Connect.
Source: Private Equity Wire